Pharmafile Logo

Infographic: RA Perceptions

HCPs predict the future of the biologics market

Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.

Download our RA Perceptions: Predicting the future of the European market infographic now »

RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.

Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.

Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.

Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.

The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Infographic: North Asia

An overview of the five most-commonly researched, largest pharma markets in North Asia.

Infographic: PsO market snapshot

An overview of the PsO biologic and systemic patientOur PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot...

Infographic: Prostate Cancer Market Snapshot

An overview of the prostate cancer patientDownload our Therapy Watch PCa market snapshot which provides you with an overview of the prostate cancer patient and the therapy regimens followed by...

Infographic: LATAM

Latin AmericaThe LATAM regions largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With...

Infographic: RA market snapshot

An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...

Infographic: CEE

The Central and Eastern Europe region is home to over 145 million people and is a key global growth region. With pharmaceutical sales set to exceed $27bn in 2014, it...

Infographic: ASEAN-6

Home to over half a billion people, the ASEAN region constitutes the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an...

Infographic: HCV – The Roadblocks to Effective Treatment

Referencing data from our Living with HCV survey undertaken with patients in the US and China, this infographic explores the roadblocks encountered on the path to effective and compliant treatment.Hepatitis C is...

Turkey: Identifying the Growth Drivers

Published in eye for pharma 3 April by Marc Yates

Article: The Patient Abroad

Published in Medical Marketing & Media March 2015